


FORM PTO-1449 (REV. 2-82)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 1103326-0636	Serial No. 09/646,852
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Lundberg et al.	
		Filing Date: September 22, 2000	Group: 1615



## UNITED STATES PATENT DOCUMENTS

*Examiner Initial	Document No.								Date	Name	Class	Sub-Class	Filing Date, if Appropriate
Len83	5	2	4	6	7	1	4		Sept. 21, 1993	Dahlinder et al.	424	497	

## FOREIGN PATENT DOCUMENTS

*Examiner Initial	Document No.								Date	Country	Class	Sub-Class	Translation Yes No	
Len83		0	1	2	4	4	9	5	7 Nov. 1984	EP	—	—		
		0	2	4	7	9	8	3	2 Dec. 1987	EP	—	—		
↓		9	8	0	0	1	1	4	8 Jan. 1998	WO	—	—		

TECH CENTER 1600/2900  
MAR 14 2003  
RECEIVED

## OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

Len83	Pilbrant, Å, et al., Development of an oral formulation of omeprazole, <u>Scandinavian Journal of Gastroenterology</u> , 20 (suppl. 108):113-120 (1985)

Examiner: Len83 Uole Bara Date Considered: 4/1/03

\*Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.